Day One Biopharmaceuticals Inc (NASDAQ: DAWN) established initial surge of 0.47% at $15.08, before settling in for the price of $15.01 at the close. Taking a more long-term approach, DAWN posted a 52-week range of $9.67-$18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -84.59%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 18.46%. This publicly-traded company’s shares outstanding now amounts to $87.23 million, simultaneously with a float of $59.32 million. The organization now has a market capitalization sitting at $1.32 billion. At the time of writing, stock’s 50-day Moving Average stood at $14.00, while the 200-day Moving Average is $14.58.
Day One Biopharmaceuticals Inc (DAWN) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Day One Biopharmaceuticals Inc industry. Day One Biopharmaceuticals Inc’s current insider ownership accounts for 32.41%, in contrast to 73.68% institutional ownership. According to the most recent insider trade that took place on Sep 10 ’24, this organization’s HEAD OF R&D sold 30,000 shares at the rate of 14.22, making the entire transaction reach 426,675 in total value, affecting insider ownership by 1,097,535. Preceding that transaction, on Aug 16 ’24, Company’s GENERAL COUNSEL sold 3,202 for 14.00, making the whole transaction’s value amount to 44,825. This particular insider is now the holder of 26,928 in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Revenue Records
Day One Biopharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 18.46% and is forecasted to reach -1.86 in the upcoming year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Let’s observe the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). It’s Quick Ratio in the last reported quarter now stands at 4.09. The Stock has managed to achieve an average true range (ATR) of 0.64. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 161.59.
In the same vein, DAWN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.93, a figure that is expected to reach -0.61 in the next quarter, and analysts are predicting that it will be -1.86 at the market close of one year from today.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Now, what If we examine the latest scores posted by [Day One Biopharmaceuticals Inc, DAWN]. During the last 5-days, its volume was better the volume of 0.92 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 84.68% While, its Average True Range was 0.64.
Raw Stochastic average of Day One Biopharmaceuticals Inc (DAWN) in the period of the previous 100 days is set at 65.28%, which indicates a major fall in contrast to 78.77% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 37.86% that was lower than 44.91% volatility it exhibited in the past 100-days period.
